Peptide Atlas · Mineral

Iron dextran

In 688,183 Medicare patients given intravenous iron, the risk of anaphylaxis at first exposure was 68 per 100,000 for iron dextran against 24 per 100,000 for the non-dextran products combined.

established

provisional
2 citations
0 discussions
0 followers
Cosmofer
Dexferrum
INFeD
high/low molecular weight iron dextran
iron(III)-dextran complex

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Iron dextran. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Low-molecular-weight iron dextran and iron sucrose have similar safety profiles in CKD (review)	emerging	pmid 18274543
Iron dextran carries the highest anaphylaxis risk among intravenous iron products (Medicare cohort)	established	pmid 26575062

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.